We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Bacterial Contamination Prompts Recall of Concentrate Used in Dialysis

Bacterial Contamination Prompts Recall of Concentrate Used in Dialysis

May 30, 2014

Massachusetts-based Fresenius Medical Care North America has issued two voluntary recalls of a concentrate used in dialysis machines over fears of bacterial contamination, the FDA said.

Fifty-six lots of Fresenius’s NaturaLyte Liquid Bicarbonate Concentrate, 6.4 liters, were pulled during the past two months because the product may develop higher bacteria levels than is allowed by the company’s internal specification, according to the recall notice.

Fresenius’ first customer notification of the Class I recall went out April 10 for 49 lots of the concentrate and the second was sent out May 1 warning of an additional nine lots.

Fresenius said the concentrate was manufactured at its facility in Montreal, Canada, and was distributed between August 2013 and April 7 of this year.

“Laboratory testing has identified the bacteria as Halomonas (species 1, 2, 3), a Gram Negative bacteria, typically found in water with high salinity,” the company said, noting that dialysate contamination has been linked with bacteremia and systemic infection.

Infection is unlikely, however, because of filters used in delivering dialysis create an effective bacteria and endotoxin barrier,” the FDA said.

The FDA announcement made no mention of any reports of people being sickened. In its second letter to customers, Fresenius said that “no pyrogenic reactions, bacterial infections or related adverse events have been reported.”

Fresenius is a division of Fresenius Medical Care, which supplies more than 2,150 dialysis centers throughout North America with dialysis equipment and products as well as renal pharmaceuticals.

Fresenius did not respond to requests for comment by press time.

Don’t let contamination cause a recall; purchase Manufacturing Sterile Products to Meet EU and FDA Guidelines today!

Medical Devices Postmarket Safety Commercial Operations

Upcoming Events

  • 13Jul

    FDA Ad and Promo Enforcement Trends: Past, Present and Future

  • 28Jul

    EU-MDR’s Growing Pains: Are You Current with the Latest Developments?

  • 28Jul

    Is Your Product a Drug or Device — and Does It Matter?: A Recent Appeals Court Decision Says It Does

  • 02Aug

    Medical Device Cybersecurity: Understand the Latest Developments

  • 03Aug

    Pharmaceutical Process Validation: Best Practices for Success

  • 10Aug

    Gene & Cell Therapy Regulation: Comparability and Other New Developments

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • FDA Provides Update on GE Healthcare’s Recall of Its Carescape R860 Ventilators

  • Gilead Resubmits NDA for Lenacapavir Following Complete Response Letter

  • FDA Warns Baby Neck Floats Used in Water Therapy Can Cause Death or Injury

  • U.S. Government Inks $3.2 Billion Contract With Pfizer-BioNTech for Vaccine Booster Campaign

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing